NOVELTY - Preparing crystalline form I of agomelatine comprises providing a solution of agomelatine in a solvent comprising tetrahydrofuran, isopropyl acetate, 1,4-dioxane, chlorobenzene or chloroform to provide a solution, adding an antisolvent to the solution, where the antisolvent comprises cyclohexane, methylcyclohexane or n-heptane, optionally seeding the solution or suspension with crystalline form I of agomelatine, and isolating crystalline form I of agomelatine.    USE - The process is useful for preparing crystalline form I of agomelatine (claimed), which is useful for treating major depression in adults. No biological data given.    ADVANTAGE - The process provides pure crystalline form I of agomelatine with improved bioavailability, stability and handling properties in an environmental friendly manner.    DETAILED DESCRIPTION - Preparing crystalline form I of agomelatine comprises: either providing a solution of agomelatine in a solvent comprising tetrahydrofuran, isopropyl acetate, 1,4-dioxane, chlorobenzene or chloroform to provide a solution, adding an antisolvent to the solution, where the antisolvent comprises cyclohexane, methylcyclohexane or n-heptane, optionally seeding the solution or suspension with crystalline form I of agomelatine, and isolating crystalline form I of agomelatine; or providing a solution of agomelatine in dimethylsulfoxide or 1,4-dioxane, adding water to the solution, and isolating crystalline form I of agomelatine. INDEPENDENT CLAIMS are included for:    (1) an amorphous solid dispersion of agomelatine together with one or more carriers;    (2) preparing the amorphous solid dispersion of agomelatine comprising providing a solution of agomelatine in combination with carriers in a solvent or mixture of solvents, removing the solvent from the solution or suspension, and isolating amorphous solid dispersion of agomelatine together with carrier; and    (3) a solid formulation comprising the amorphous solid dispersion of agomelatine or crystalline form I agomelatine and carrier.